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Abstract
Background: Despite cost containment efforts, parenteral (IV) ciprofloxacin appears to be overutilized at Vancouver
General Hospital. In November 2003, the Pharmacist-managed intravenous to oral (IV-PO) Dosage Form Conversion
Service was implemented, enabling autonomous pharmacist-initiated dosage form conversion for ciprofloxacin. This
study evaluates characteristics of ciprofloxacin use prior to and following implementation of this conversion service.
Methods: This was a single-centre, two-phase (pre/post), unblinded study. Phase I occurred between November 12,
2002 and November 11, 2003 (365 days), and Phase II between November 12, 2003 and March 11, 2004 (120 days). All
patients receiving ciprofloxacin IV during these periods were reviewed. The primary endpoint was IV:PO ciprofloxacin
use ratio. Secondary endpoints were total number of ciprofloxacin doses, proportion of inappropriate IV ciprofloxacin
doses, cost of therapy between phases, and estimated cost avoidance with the intervention.
Results: Two hundred ciprofloxacin IV treatment courses were evaluated (100 per phase). The IV:PO ciprofloxacin use
ratio was 3.03 (Phase I) vs. 3.48 (Phase II). Total number of doses and ratio of IV to total doses across phases were similar
(p = 0.2830). IV-PO ciprofloxacin conversion occurred in 27/100 (27%) of IV courses in Phase I and 23/100 (23%) in Phase
II. Proportion of inappropriate ciprofloxacin IV doses decreased between Phases I and II (244/521 (47%) vs. 201/554
(36%) (p = 0.0005), respectively). Furthermore, the proportion of pharmacist-preventable inappropriate ciprofloxacin IV
doses was reduced between Phases I and II (114/244 (47%) vs. 65/201 (32%) (p = 0.0026). Proportional cost avoidance
associated with total inappropriate IV use was $7,172/$16,517 (43%) (in Canadian dollars) in Phase I vs. $6,012/$17,919
(34%) in Phase II (p = 0.001). Similarly, proportional cost avoidance associated with pharmacist-preventable inappropriate
IV doses was reduced from $3,367/$16,517 (20%) in Phase I to $1,975/$17,919 (11%) in Phase II (p = 0.001).
Conclusion: While overall utilization of ciprofloxacin remained unchanged and the proportion of IV to total doses was
stable during the study period, the proportion of inappropriate IV doses and its associated costs appear to have declined
subsequent to implementation of a Pharmacist-managed IV-PO Dosage Form Conversion Service. Such a program may
be a beneficial adjunct in facilitating appropriate and cost-effective usage of ciprofloxacin.
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Background
The annual drug expenditures at Vancouver Hospital are
approximately $13 million (in Canadian dollars). At the
Vancouver General Hospital (VGH) site, anti-infectives
accounted for an expenditure of $3.39 million or 25% of
the 2002–03 fiscal year total drug costs. Ciprofloxacin
ranked third among all drugs by cost and was the second
highest annual expenditure within the anti-infective drug
class at $646,000. In addition, ciprofloxacin expenditures
increased 5% from the previous year. Of the 39,147 cipro-
floxacin doses administered in the 2002–03 fiscal year,
18,297 doses (47%) were given intravenously (IV).
Ciprofloxacin is a fluoroquinolone antibacterial that is
primarily active against aerobic gram-negative bacterial
infections [1]. It can be administered via the IV and oral
(PO) routes. Concentrations similar to those achieved
with the IV formulation are possible when administering
ciprofloxacin orally, as it is highly bioavailable [2,3]. The
daily drug cost (including material and labour costs for
dispensing, preparation, and administration) of a typical
ciprofloxacin 400 mg IV regimen administered twice daily
is $72.62 [4]. Conversely, the daily drug cost of an equiv-
alent ciprofloxacin 500 mg PO regimen given twice daily
is $8.48, or 12% of the IV regimen [4].
In an effort to optimize use and minimize drug expendi-
tures, ciprofloxacin has been designated a reserved anti-
microbial drug (RAD) at our institution and has been
included in the existing intravenous to oral (IV-PO) Step-
down Program since 1992 [5]. Under this initiative, the
use of the PO formulation of ciprofloxacin has been pro-
moted at our institution through the means of newsletters
[6], chart talkers and notes [7,8], and direct pharmacist-
physician interactions. Other drugs included in this pro-
gram are cefuroxime, cefixime, clindamycin, fluconazole,
levofloxacin, and metronidazole.
Despite these cost containment efforts, there is some evi-
dence to suggest that the IV formulation of these drugs
may not be optimally utilized. Previous investigations by
others and ourselves have shown that the IV formulation
is often initiated when the PO formulation can be used [9-
13]. Of equal importance, conversion to the PO formula-
tion does not appear to be undertaken in a timely manner
[6,10,11,13,14]. This results in unnecessary medication
costs, IV drug administration expenses, and potential
exposure to adverse events associated with IV therapy (e.g.
pain at injection site, phlebitis, and line infections).
Various authors have described criteria-based medication
dosage form conversion programs in the literature
[8,10,11,13,15-24]. Some institutions have implemented
modified IV-PO conversion programs in which pharma-
cists are given the authority and responsibility to change
dosage forms in accordance with established criteria (i.e.
clinical stability of the patient, ability to tolerate PO med-
ications, and lack of drug interactions that may impair
drug absorption from the gastrointestinal tract)
[10,17,18,23,24]. The anticipated benefit of a pharmacist-
managed conversion program is that delays in IV-PO con-
version will be reduced if a pharmacist can avoid the
requirement of conferring with the initiating physician
before commencing a dosage form change. These services
have demonstrated that cost savings can be achieved
when pharmacists are directly responsible for changing
the route of administration for selected medications [24].
In November 2003, the Pharmacist-managed IV-PO Dos-
age Form Conversion Service was approved at VGH by the
Antibiotic Use Subcommittee (AUS), Drugs and Thera-
peutics Committee (D&TC), and the Medical Advisory
Committee (MAC). Several antimicrobial agents were
included in this service; namely, ciprofloxacin, clindamy-
cin, co-trimoxazole, fluconazole, levofloxacin, metroni-
dazole, acyclovir, ampicillin, cefazolin, cefuroxime,
penicillin G, ceftriaxone, imipenem-cilastatin, cloxacillin,
erythromycin, and ticarcillin-clavulanate [25].
Our hypothesis was that ciprofloxacin IV was overutilized
at VGH and that a more cost-effective use of this dosage
form was possible with the implementation of a Pharma-
cist-managed IV-PO Dosage Form Conversion Service.
Accordingly, this study was conducted to assess the impact
of this service on the relative utilization of the IV versus
PO dosage form of ciprofloxacin. To our knowledge, there
are no published reports involving an assessment of the
impact of a Pharmacist-managed IV-PO Dosage Form
Conversion Service on ciprofloxacin usage characteristics
at a major Canadian teaching hospital.
Methods
Literature review
A literature search of the Medline, EMBASE and IPA data-
bases, as well as a bibliographic review from the cited arti-
cles was performed to retrieve references pertaining to
pharmacy-managed IV-PO conversion programs. Addi-
tional references were obtained through the St. Paul's
Hospital and Lions' Gate Hospital pharmacy depart-
ments, as these local institutions had established pharma-
cist-managed conversion services [18,23]. The
information collected was used to formulate a policy and
procedure for the Pharmacist-managed IV-PO Conversion
Service at our institution. This document was approved by
the AUS, D&TC, and MAC, and a hospital-wide service
was implemented.
Study design
This was a single-centre, 2-phase (pre/post), unblinded
study to assess the impact of a hospital-approvedBMC Health Services Research 2005, 5:48 http://www.biomedcentral.com/1472-6963/5/48
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intervention aimed at improving the utilization of cipro-
floxacin dosage forms. Phase I (365 days; November 12,
2002 to November 11, 2003) was designed to characterize
ciprofloxacin usage patterns under the existing IV-PO
Step-down Program. Phase II (120 days; November 12,
2003 to March 11, 2004) was designed to characterize the
impact of the new Pharmacist-managed Dosage Form
Conversion Service (implemented on November 12,
2003) on the relative utilization of the ciprofloxacin IV
and PO dosage forms.
The primary endpoint was the relative utilization of IV
and PO ciprofloxacin by dose (IV:PO ciprofloxacin use
ratio). The secondary endpoints were the overall utiliza-
tion of ciprofloxacin (by dose), the proportion of total IV
doses considered to be inappropriate, and relative IV and
PO total and treatment course acquisition costs between
the two phases. Potential cost avoidance associated with
the intervention was estimated from the data.
Intervention
Prior to the implementation of the program, pharmacists
were educated on the approved conversion service
through in-house presentations. A newsletter was distrib-
uted to all medical staff detailing the program [25].
Decentralized clinical pharmacists on the medical wards
were expected to conduct target drug report reviews 5 days
per week to identify inpatients who had been prescribed
ciprofloxacin IV. Health records were then reviewed, and
patients assessed to determine if IV-PO conversion criteria
were met. A patient was eligible for IV-PO dosage form
conversion after 48 hours of IV therapy if he/she 1) con-
tinued to need an antibiotic; 2) was clinically stable; 3)
was capable of tolerating the PO dosage form; and 4) had
no factors present that would adversely affect PO bioavail-
ability (e.g. gastrointestinal abnormalities or drug interac-
tions). Pharmacists could consult the Infectious Diseases
service or Infectious Diseases Pharmacist at anytime with
any questions regarding IV-PO conversion eligibility.
For patients who met the conversion criteria, the pharma-
cist would write the order for the PO regimen in the Phy-
sician's Orders section of the health record. If the
pharmacist wanted to convert the patient to PO cipro-
floxacin prior to 48 hours of IV therapy, they would first
confer with the physician. In collaboration with the
healthcare team, the pharmacist would monitor the
patient for clinical progress and medication tolerability,
and could convert the patient back to IV therapy as
required.
A randomly selected convenience sample of 200 cipro-
floxacin IV treatment courses (100 treatment courses per
phase) was considered to be adequate to determine the
impact of this new intervention. These courses were iden-
tified using computerized pharmacy records and a ran-
dom sample was undertaken using a computer-generated
number list.
All patients who were ordered ciprofloxacin IV were
included in the sample collection. Patients were excluded
if they did not receive any doses of ciprofloxacin IV, if
their ciprofloxacin IV treatment course did not occur
within the pre-specified phase to which they were rand-
omized, or if their charts were unavailable from the
Health Records department at VGH as of July 14, 2004.
Charts were reviewed to gather demographic data, cipro-
floxacin utilization information, inappropriate IV doses,
and pharmacist-preventable IV doses of ciprofloxacin.
Data collection and analysis
Data was collected by one investigator and entered into
statistical analysis software (SPSS©  Version 11.0). Any
treatment course that this investigator considered to have
four or more inappropriately administered ciprofloxacin
IV doses was reviewed in collaboration with the coordi-
nating investigator to ensure accuracy of interpretation.
Inferential statistics were performed. A two-sample Stu-
dent's t-test was used for parametric data, the Mann-Whit-
ney test was used for non-parametric data, and the Fisher's
Exact and Chi-square tests were used for proportional
analyses.
Definitions
For the purposes of this study, a ciprofloxacin IV dose was
considered "inappropriate" when the patient met the cri-
teria for use of the PO dosage form. A ciprofloxacin IV
dose was considered "pharmacist-preventable" if the dose
was administered when the patient met the criteria for use
of the PO dosage form and the decentralized clinical phar-
macist was considered to have had the opportunity to
intervene (i.e. Monday to Friday between 08:00 and 16:00
hours, excluding statutory holidays). The inappropriate
IV-PO ciprofloxacin acquisition cost was the differential
cost between the IV and the PO dosage form at current
contract prices multiplied by the number of inappropriate
IV doses administered.
Results
Two hundred and fifteen health records of patients who
were prescribed ciprofloxacin IV during the study period
were reviewed. Of these, seven patients were excluded, as
the ciprofloxacin IV treatment courses were not com-
pleted within the pre-specified treatment phase. Six
patients were excluded, as no IV ciprofloxacin doses were
actually received. Health records were not accessible at the
time of the study for the remaining two patients.BMC Health Services Research 2005, 5:48 http://www.biomedcentral.com/1472-6963/5/48
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Accordingly, 200 treatment courses for 200 patients (100
per phase) were included for analysis. This represented a
4% (100/2411 treatment courses) sampling rate for Phase
I and a 10% (100/994 treatment courses) sampling rate
for Phase II.
Patient demographics are presented in Table 1. Patients
receiving ciprofloxacin IV were equally distributed by gen-
der, typically in their sixth/seventh decade of life with an
average duration of hospital stay of approximately two
weeks. Treatment courses were initiated in both surgical
and medical service areas for a wide variety of infectious
indications. There were no significant differences between
the two phases in terms of age, gender, renal function,
length of stay, and medical service area to which the
patients were assigned. Most patients (75% in Phase I,
78% in Phase II) received IV ciprofloxacin in combination
with one or more antibiotics.
Of the 200 ciprofloxacin IV courses reviewed, the total
number of doses and the ratio of IV to total doses across
phases were similar (p = 0.2830) (Figure 1). The IV:PO
ciprofloxacin use ratio was 3.03 in Phase I vs. 3.48 in
Phase II.
Ciprofloxacin treatment characteristics are described in
Table 2. No significant differences were observed between
the initial ciprofloxacin dosing strengths (p = 1.00), the
initial dosing frequencies (p = 0.55), and the number of
IV-PO conversions per treatment course (p = 0.73). IV-PO
ciprofloxacin conversion occurred in 27/100 (27%) of IV
treatment courses in Phase I and 23/100 (23%) of courses
in Phase II (Table 2). The number of IV-PO conversions
that were subsequently reversed to IV was 2 cases in Phase
I and 3 cases in Phase II. Chart documentation of a phar-
macist-initiated IV-PO conversion was recorded in 3/27
(11%) episodes in Phase I and 4/23 (17%) episodes in
Phase II. There was no difference between phases with
respect to the median number of ciprofloxacin doses
Table 1: Patient demographics
Phase I Nov. 12, 02 to Nov. 11, 03 (365 
days)
Phase II Nov. 12, 03 to Mar. 11, 04 (120 
days)
No. of patients 100 100
No. of treatment courses 100 100
Age (yr), median (range) 57 (17–93) 63 (16–91)
Gender, N
Male 45 50
SCr1 (µmol/L), median (range) 84 (40–541) 89 (35–641)
Length of Stay (d), mean (range) 12 (1–84) 17 (1–165)
Service Area, N
General Surgery 31 30
Medicine 22 11
Emergency 15 11
Intensive Care Unit 7 8
Urology 3 12
Other 222 283
Indication, N
Off-label indications4 38 35
Intra-abdominal infection 18 15
Respiratory tract infection 15 16
Urinary tract infection 15 15
Other 145 196
1Serum creatinine closest to start of ciprofloxacin IV treatment.
2 Other service areas: Thoracic, Respiratory, Spine, Hematology/BMT, Transplant, Cardiothoracic Surgery, Neurosciences Intensive Care Unit, 
Cardiology, Day Bed Unit, Same Day Admit Unit, Pre-admission Clinic, Trauma Special Care Unit, Neurosciences, Family Practice, Orthopedics, 
Vascular, and Gynecology.
3 Other service areas: Thoracic, Spine, Hematology/BMT, Transplant, Cardiology, Day Bed Unit, Same Day Admit Unit, Neurosciences, Family 
Practice, Vascular, Gynecology, Palliative Care, and Trauma.
4Off-label indications refer to those not approved on the manufacturer's drug monograph.
5Other indications: Empiric therapy in febrile neutropenia, skin and soft tissue, and septicemia.
6 Other indications: Empiric therapy in febrile neutropenia, skin and soft tissue, septicemia, and infectious diarrhea.BMC Health Services Research 2005, 5:48 http://www.biomedcentral.com/1472-6963/5/48
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administered and the median costs associated with each
treatment course (Table 2).
For those patients who met the criteria for the use of an
oral dosage form, 59/100 (59%) received one or more
inappropriate doses of ciprofloxacin IV in Phase I com-
pared to 61/100 (61%) in Phase II. There was a significant
decrease in the proportion of inappropriate ciprofloxacin
IV doses between phases (244/521 (47%) in Phase I vs.
201/554 (36%) in Phase II (p = 0.0005) (Figure 2). Fur-
thermore, there was a significant reduction in the propor-
tion of pharmacist-preventable inappropriate
ciprofloxacin IV doses between Phase I and Phase II (114/
244 (47%) vs. 65/201 (32%) (p = 0.0026) (Figure 2).
The total cost of IV and PO ciprofloxacin for the treatment
courses reviewed was $16,993 in Phase I and $18,332 in
Phase II. Ciprofloxacin IV accounted for $16,517 (97%)
of total ciprofloxacin costs in Phase I and $17,919 (98%)
of these costs in Phase II (Figure 3). The proportional cost
avoidance associated with inappropriate use of IV cipro-
floxacin was $7,172/$16,517 (43%) in Phase I compared
to $6,012/$17,919 (34%) in Phase II (p = 0.001). The
proportional pharmacist-preventable cost avoidance asso-
ciated with inappropriate IV ciprofloxacin use was
reduced from $3,367/$16,517 (20%) in Phase I to
$1,975/$17,919 (11%) in Phase II (p = 0.001).
Discussion
The purpose of this study was to assess the relative utiliza-
tion of the IV and PO dosage form of ciprofloxacin
subsequent to the implementation of the Pharmacist-
managed Dosage Form Conversion Service. We did not
aim to assess the appropriateness of ciprofloxacin usage
for specific indications.
Overall, the IV:PO ratio of ciprofloxacin usage remained
similar between the two phases, and the total number of
ciprofloxacin doses did not change significantly. Initially,
it was anticipated that implementation of the conversion
service would reduce the IV:PO ratio, however, there were
numerous variables that may have affected this endpoint.
We were also interested in evaluating whether the number
of inappropriate IV doses and pharmacist-preventable
inappropriate IV doses could be reduced. Our results
showed a 23% relative reduction in the proportion of
inappropriate ciprofloxacin IV doses and a 32% relative
reduction in the incidence of pharmacist-preventable
inappropriate ciprofloxacin IV doses subsequent to the
intervention.
A possible explanation for the decline in the inappropri-
ate and pharmacist-preventable inappropriate cipro-
floxacin IV doses was the drive to reduce hospital
expenditures at our institution at the time this program
was implemented. There was an increased awareness and
emphasis for cost-effective prescribing. The conversion
service was an adjunct to the cost savings initiatives and
was readily adapted to our established practice.
VGH has had a pre-existing IV-PO Step-Down Program
since 1992. In a previous study at our institution in 1992,
the rate of patients eligible for IV-PO conversion was 52%,
which is similar to the 59% observed in Phase I of our
present study [6]. The rate of IV-PO conversions in 1992
was also comparable to our baseline in Phase I (34% vs.
27%, respectively). This suggests that the interventions of
our IV-PO Step-down Program have remained relatively
constant since 1992. With an effective IV-PO Step-down
Program in place, it is possible that the magnitude of
change associated with the implementation of the conver-
sion service may have been blunted.
Total number of ciprofloxacin doses Figure 1
Total number of ciprofloxacin doses. p = 0.2830 for 
ratio of IV to total number of ciprofloxacin doses between 
phases.
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Pharmacist-initiated IV-PO conversion was documented
in the health record in 4 cases in Phase I and 3 cases in
Phase II. This low incidence of documentation may be
attributed to the activities of the decentralized clinical
pharmacists who attend patient care rounds and interact
directly with physicians, so that orders are written during
rounds for IV-PO conversion. Greater awareness of other
health care professionals on the bioavailability of PO cip-
rofloxacin may also have resulted in the earlier usage of
the PO dosage form.
Total costs of ciprofloxacin therapy were similar between
the two phases. This was expected, as the conversion
service would not alter the indications for ciprofloxacin
use. However, the costs associated with inappropriate cip-
rofloxacin IV therapy and pharmacist-preventable inap-
propriate ciprofloxacin IV therapy declined from Phase I
to II, which may be attributed to the increased interven-
tions of the clinical pharmacists and the improved aware-
ness for PO therapy post intervention.
Following implementation of the conversion service, 12%
(65/554) of ciprofloxacin doses deemed inappropriate
and preventable by pharmacists were still administered.
Ideally, all of these doses should have been avoided. One
full working day (excluding weekends and statutory holi-
days) was allotted as the time required for clinical phar-
macists to assess these patients. This delay in IV-PO
conversion may be explained in part by having our data
collection period immediately after the introduction of
the new service, as pharmacists may not yet have been
comfortable exercising a dosage form conversion autono-
mously. The retrospective assessment for appropriateness
by the investigator may also differ from that of the clinical
pharmacist. It would be beneficial to obtain an internal
assessment to discover the barriers associated with the
program. Of course, it would be preferable to educate the
medical staff to initiate PO regimens where indicated and
avoid the use of the IV formulation.
Several limitations exist with this study. The retrospective,
pre/post, unblinded design precludes the formulation of
any direct causal relationships between the implementa-
tion of the conversion service and the subsequent reduc-
tion in inappropriate ciprofloxacin IV doses. The sample
size of convenience may not have achieved the power
required to detect a difference. In addition, the sampling
rate was relatively low at 4.1% (100/2411 ciprofloxacin IV
courses) in Phase I and 10.1% (100/994) in Phase II, and
thus may not truly represent the characteristics of our pop-
ulation. Time restrictions resulted in differences in sam-
pling periods between Phase I (365 days) and Phase II
(120 days), which may affect the representation of cipro-
floxacin IV treatment courses throughout the year. How-
ever, this should not directly influence the proportion of
inappropriate and pharmacist-preventable inappropriate
ciprofloxacin IV treatment doses. The assessment of this
service was over a relatively short period, and so may not
truly reflect the long-term impact of this program.
Table 2: Ciprofloxacin treatment course characteristics
Phase I Phase II P value
Treatment regimen characteristics
Dosing Strength 1.00
200 mg IV 6 6
400 mg IV 94 94
Dosing Frequency 0.55
Once 17 22
Once daily 5 3
Twice Daily 78 75
IV to PO Conversion Rate (% by treatment course) 27 23 0.73
Ciprofloxacin doses/treatment course, median (range) 5 (1–33) 5 (1–44) 0.55
IV, median (range) 3 (1–33) 4 (1–25) 0.29
Inappropriate IV, mean (range) 2.4 (0–26) 2.0 (0–9) 0.33
Inappropriate & pharmacist-preventable IV, mean (range) 1.1 (0–24) 0.6 (0–6) 0.14
PO, mean (range) 1.7 (0–26) 1.6 (0–26) 0.83
Treatment course acquisition costs ($)
Ciprofloxacin, median (range) 99 (17–1089) 132 (17–825) 0.32
IV, median (range) 99 (17–1089) 132 (17–825) 0.28
Inappropriate IV, mean (range) 72 (0–790) 60 (0–274) 0.39
Inappropriate & pharmacist-preventable IV, mean (range) 34 (0–729) 20 (0–182) 0.17BMC Health Services Research 2005, 5:48 http://www.biomedcentral.com/1472-6963/5/48
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As with any unblinded study of this type, the potential for
investigator assessment bias existed. As the evaluation of
dose appropriateness was undertaken sequentially across
phases, potential bias may have been introduced as the
investigator gained experience during the process. To
minimize this bias, charts were reviewed by a senior inves-
tigator when greater than four inappropriate and pharma-
cist-preventable inappropriate ciprofloxacin IV doses were
identified by the junior investigator. A 100% concordance
existed between the assessments made by the junior and
senior investigators.
In the context of drug use optimization and cost minimi-
zation, implementation of a Pharmacist-managed IV-PO
Dosage Form Conversion Service may be used to facilitate
appropriate, cost-effective therapy. This service can be
used in conjunction with other established methods
including newsletters [6], chart talkers, notes [7,8], and
direct pharmacist-physician interactions. To further pro-
mote antimicrobial use appropriateness, strategies aimed
at affecting prescribing behaviour may be employed.
These include individual physician prescribing feedback,
multidisciplinary inservices in collaboration with infec-
tious diseases physicians, and prescriber education
through academic detailing.
Conclusion
In summary, the overall utilization of ciprofloxacin seems
to have remained unchanged and the proportion of IV to
Number of total, inappropriate, and pharmacist-preventable  inappropriate IV ciprofloxacin doses Figure 2
Number of total, inappropriate, and pharmacist-pre-
ventable inappropriate IV ciprofloxacin doses. p = 
0.0005 for difference in the proportions of inappropriate IV 
ciprofloxacin doses between phases. p = 0.0026 for differ-
ence in the proportions of pharmacist-preventable inappro-
priate IV ciprofloxacin doses between phases.
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total doses appears stable. However, the proportion of
inappropriate IV doses and its associated costs appear to
have declined subsequent to the implementation of a
Pharmacist-managed IV-PO Dosage Form Conversion
Service. Such a program may be a beneficial adjunct in
facilitating appropriate and cost-effective usage of
ciprofloxacin.
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